The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
New research suggests that it could be possible to separate treatment from hallucinations when developing new drugs based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback